Well, joining me now is the administrator of the Centers for Medicare and Medicaid Services, Dr.. Medmmetz. Dr.. Oz, thank you so much for joining me. Really appreciate it. >> Honor to be with you, Kristen. Thank you for having me. >> Well, it's wonderful to have you here, Dr.. Oz. I want to start off by asking you about open enrollment for the Obamacare marketplace. These subsidies, open enrollment, of course, begins November 1st. It's already underway for Medicare recipients. I want to ask you if the ACA ...

Mark Cuban, thank you so much for sitting down with us to talk here at health. >> You know, I I was just thinking >> it was only 2022 when you launched cost plus. It seems as though we've been having this conversation for a long time.>> Yeah. >> So much has happened in those three years. >> Where do you feel you are.Are you where you thought cost plus would be. Honestly, from the day we launched with 111 medications, we're so much further than I ever expected. Um, the response has just been through the roof ...

AstraZeneca is the latest major drugmaker to strike a deal with the Trump administration on lowering U.S. drug prices https://t.co/3H5nCVbMoC ...

Americans would welcome lower drug prices. But without more transparency, it's impossible to tell if President Trump's plan benefits consumers as much as Big Pharma, @lisamjarvis says (via @opinion) https://t.co/BPhsOSZmyv ...

Drug Pricing - Amgen 通过新的药物获取计划，将美国患者的胆固醇药物价格降低了一半以上 [1] - 此举正值特朗普政府呼吁降低药品价格之际 [1]

The deal with Pfizer has allowed Trump to finally claim progress toward ending what he views as unfair foreign freeloading off of high drug prices that Americans pay.Here's how it happened ⤵️ https://t.co/BTvtbuu8cZ ...

Drug Pricing & Accessibility - Pfizer commits to offering all prescription medications to Medicaid at most favored nation prices, aiming to significantly reduce Medicaid costs [1] - Pfizer agrees to provide some popular medications to all consumers at heavily discounted prices, ranging from 50% to 100% off, available for direct purchase online via a federal government website [2] - All new medications introduced by Pfizer to the American market will be sold at reduced most favored nation costs, aligning with prices paid by other countries [3] - The agreement aims to bring down drug prices immediately for Americans [8] Manufacturing & Investment - Pfizer will invest $70 billion to reshore domestic manufacturing facilities, relocating production to the United States [3][4] - Pfizer commits to source the production of medicines consumed in the US from within the US, unleashing its investment portfolio in the country [5] - Pfizer is granted a three-year grace period from tariffs as long as they move production to the US [5] Negotiation & Tariffs - The administration is negotiating deals with other companies, with Pfizer being the first [6] - The administration is prepared to impose tariffs of an equivalent amount if companies refuse to make a deal, removing the advantage of non-compliance [7]

Regulatory Focus - FDA is cracking down on misleading drug company ads by sending thousands of warning letters and about 100 cease and desist letters [1][6] - FDA aims to close a regulation loophole from 1997 that allowed companies to put side effects on a website instead of in the ad, requiring more disclosures and potentially longer ads [4] - FDA enforcement of existing regulations had dwindled, with only one enforcement letter sent in 2023 and none the previous year, but recently 108 cease and desist letters and over 1,500 warning letters were sent [5][6] Industry Practices & Concerns - Pharmaceutical companies spend over 10 billion USD on ads in the United States, which can be 20-25% of a company's budget [7] - Doctors believe these ads distort the doctor-patient relationship by creating increased demand for medications, often expensive ones, regardless of clinical appropriateness [3] - The marketing often focuses on creating demand without informing people what the drug is used for, leading to patients asking their doctors for specific medications [8][13][14] - The increase in drug spend since 1997, 31% is attributed to pharmaceutical direct-to-consumer ads [11] - The US healthcare system is facing an overmedication crisis, contributing to a "pill-popping culture" [11][12][13] Potential Solutions & Perspectives - The administration suggests companies use the money spent on ads to lower drug prices for everyday Americans [7] - Some pharma CEOs have expressed privately that they would like to see these ads go away, feeling pressured to run them [17][18] - Addressing pharmaceutical ads is seen as a significant reform to address overmedication and high drug spending in the United States [12][13]

Pharmaceutical Pricing & Policy - The Trump administration is attempting to lower drug prices in the US, potentially through negotiation and jawboning, after previous regulatory efforts were struck down by courts [1][3][4] - The administration proposes that new drug launches in commercial and Medicare markets should adopt the Most Favored Nation (MFN) price prospectively, but applying MFN pricing to Medicaid from day one could significantly impact pharmaceutical company revenues [5][6] - A tiered pricing system based on a nation's wealth (GDP per capita) is suggested as a fairer global approach to drug pricing, with different prices for low, middle, and high-income nations [7] - The US Trade Representative (USTR) should support pharmaceutical companies in pushing back against global pricing authorities, potentially leading to higher prices in other developed countries alongside lower prices in the US [8][9][10][20] - The administration is considering a direct-to-consumer online portal where underinsured or uninsured individuals can purchase heavily rebated drugs at MFN-type pricing [13] FDA & Regulatory Environment - The FDA is experiencing a significant loss of scientific staff, with the Biologic Center seeing 106 departures since the beginning of the year, in addition to 150 RIFs (reductions in force), and the Drug Center losing a third of reviewers for breast and gynecological cancer products and over half of the malignant heme products group [25][26] - The quality and pace of interactions between early-stage companies and the FDA have decreased due to staff departures and firings [27][28] - There are concerns about political meddling and intrusion in the FDA's decision-making, potentially affecting the agency's morale and scientific judgment [31][32]

AstraZeneca CEO broke ranks with his pharmaceutical industry peers Tuesday, saying he was open to aligning drug prices globally https://t.co/eQHyxQ8wwF ...